{"downloaded": true, "htmlmade": false, "full": {"id": "29895931", "source": "MED", "pmid": "29895931", "pmcid": "PMC6365372", "fullTextIdList": {"fullTextId": "PMC6365372"}, "doi": "10.1038/s41409-018-0253-y", "title": "A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing \u226470\u2009kg.", "authorString": "Kuruvilla J, Tzeng CH, Cho SG, Kim SJ, Tang JL, Su Y, Wu J, Vargo R, Cheverton P.", "authorList": {"author": [{"fullName": "Kuruvilla J", "firstName": "John", "lastName": "Kuruvilla", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Princess Margaret Cancer Centre, Toronto, Canada. john.kuruvilla@uhn.on.ca."}}}, {"fullName": "Tzeng CH", "firstName": "Cheng-Hwai", "lastName": "Tzeng", "initials": "CH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Taipei Veterans General Hospital, Taipei, Taiwan."}}}, {"fullName": "Cho SG", "firstName": "Seok-Goo", "lastName": "Cho", "initials": "SG", "authorId": {"@type": "ORCID", "#text": "0000-0002-5429-4839"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Catholic Medical Centre St Mary's Hospital, Seoul, Korea."}}}, {"fullName": "Kim SJ", "firstName": "Seok Jin", "lastName": "Kim", "initials": "SJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Samsung Medical Centre, Seoul, Korea."}}}, {"fullName": "Tang JL", "firstName": "Jih-Luh", "lastName": "Tang", "initials": "JL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "National Taiwan University Hospital, Taipei, Taiwan."}}}, {"fullName": "Su Y", "firstName": "Yaming", "lastName": "Su", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sanofi Oncology, Cambridge, MA, USA."}}}, {"fullName": "Wu J", "firstName": "Jingyang", "lastName": "Wu", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sanofi Oncology, Cambridge, MA, USA."}}}, {"fullName": "Vargo R", "firstName": "Rita", "lastName": "Vargo", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sanofi Oncology, Cambridge, MA, USA."}}}, {"fullName": "Cheverton P", "firstName": "Peter", "lastName": "Cheverton", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sanofi Oncology, Cambridge, MA, USA."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-5429-4839"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "2", "volume": "54", "journalIssueId": "2779996", "dateOfPublication": "2019 Feb", "monthOfPublication": "2", "yearOfPublication": "2019", "printPublicationDate": "2019-02-01", "journal": {"title": "Bone marrow transplantation", "ISOAbbreviation": "Bone Marrow Transplant", "medlineAbbreviation": "Bone Marrow Transplant", "NLMid": "8702459", "ISSN": "0268-3369", "ESSN": "1476-5365"}}, "pubYear": "2019", "pageInfo": "258-264", "abstractText": "A randomized, multicenter, open-label study explored the effect of a fixed-dose (FD) of plerixafor versus the approved weight-based (WB) dose for the mobilization of hematopoietic stem cells (HSCs) in patients with non-Hodgkin's lymphoma and a body weight of \u226470\u2009kg. After mobilization with granulocyte colony-stimulating factor (G-CSF) 10\u2009\u03bcg/kg/day for 4 days, patients were randomized 1:1 to either plerixafor FD 20\u2009mg (n\u2009=\u200930) or WB 0.24\u2009mg/kg (n\u2009=\u200931) on the evening of Day 4. Co-primary endpoints were the proportion of patients achieving \u22655\u2009\u00d7\u200910<sup>6</sup> CD34<sup>+</sup> cells/kg in \u22644 days of apheresis, and total systemic exposure to plerixafor (area under the concentration-time curve from 0 to 10\u2009h [AUC<sub>0-10</sub>]). There was no statistically significant difference between the proportion of patients attaining the primary efficacy endpoint (60% FD arm, 55% WB arm; P\u2009=\u20090.395). Exposure to plerixafor was greater in the FD arm relative to the WB arm; however, there was no appreciable difference regarding fold increases of peripheral blood CD34<sup>+</sup> cells. The safety profile was similar between treatment groups. These results suggest there is no statistically significant difference in HSC mobilization with a standard WB dosing regimen of plerixafor plus G-CSF in patients with low body weight compared with an FD regimen.", "affiliation": "Princess Margaret Cancer Centre, Toronto, Canada. john.kuruvilla@uhn.on.ca.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article", "Clinical Trial, Phase IV"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, Non-Hodgkin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Body Weight"}, {"majorTopic_YN": "N", "descriptorName": "Thinness"}, {"majorTopic_YN": "N", "descriptorName": "Heterocyclic Compounds", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Granulocyte Colony-Stimulating Factor", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antigens, CD34", "meshQualifierList": {"meshQualifier": {"abbreviation": "AN", "qualifierName": "analysis", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Mobilization", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}, {"abbreviation": "ST", "qualifierName": "standards", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Transplantation", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "Y", "descriptorName": "Drug Dosage Calculations"}]}, "chemicalList": {"chemical": [{"name": "Heterocyclic Compounds", "registryNumber": "0"}, {"name": "Granulocyte Colony-Stimulating Factor", "registryNumber": "143011-72-7"}, {"name": "Antigens, CD34", "registryNumber": "0"}, {"name": "plerixafor", "registryNumber": "S915P5499N"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1038/s41409-018-0253-y"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6365372"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6365372?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2020-02-24", "dateOfCreation": "2018-06-14", "firstIndexDate": "2018-06-14", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2021-02-26", "electronicPublicationDate": "2018-06-12", "firstPublicationDate": "2018-06-12"}, "htmllinks": "https://europepmc.org/articles/PMC6365372", "abstract": "A randomized, multicenter, open-label study explored the effect of a fixed-dose (FD) of plerixafor versus the approved weight-based (WB) dose for the mobilization of hematopoietic stem cells (HSCs) in patients with non-Hodgkin's lymphoma and a body weight of \u226470\u2009kg. After mobilization with granulocyte colony-stimulating factor (G-CSF) 10\u2009\u03bcg/kg/day for 4 days, patients were randomized 1:1 to either plerixafor FD 20\u2009mg (n\u2009=\u200930) or WB 0.24\u2009mg/kg (n\u2009=\u200931) on the evening of Day 4. Co-primary endpoints were the proportion of patients achieving \u22655\u2009\u00d7\u200910<sup>6</sup> CD34<sup>+</sup> cells/kg in \u22644 days of apheresis, and total systemic exposure to plerixafor (area under the concentration-time curve from 0 to 10\u2009h [AUC<sub>0-10</sub>]). There was no statistically significant difference between the proportion of patients attaining the primary efficacy endpoint (60% FD arm, 55% WB arm; P\u2009=\u20090.395). Exposure to plerixafor was greater in the FD arm relative to the WB arm; however, there was no appreciable difference regarding fold increases of peripheral blood CD34<sup>+</sup> cells. The safety profile was similar between treatment groups. These results suggest there is no statistically significant difference in HSC mobilization with a standard WB dosing regimen of plerixafor plus G-CSF in patients with low body weight compared with an FD regimen.", "pdflinks": "https://europepmc.org/articles/PMC6365372?pdf=render", "journaltitle": "Bone marrow transplantation", "authorinfo": ["Kuruvilla J", "Tzeng CH", "Cho SG", "Kim SJ", "Tang JL", "Su Y", "Wu J", "Vargo R", "Cheverton P"], "title": "A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing \u226470\u2009kg."}